. Author manuscript; available in PMC: 2019 Jul 16.

Published in final edited form as: Pharmacogenomics J. 2009 Dec 29;10(3):191–199. doi: 10.1038/tpj.2009.57

Table 2.

Patient characteristics

No. of patients	47
Age, years^a	66.1 (41–79)
Race
Caucasian	43
African American	3
Asian	1
Gleason at diagnosis^a	7.9 (6–10)
Baseline PSA^a	252 (5–1068)
Trial arm^b
Docetaxel	14
Docetaxel and thalidomide	33
Response
Docetaxel	7 (50%)
Docetaxel and thalidomide	24 (73%)

Data are expressed as the median value and range.

The original trial consisted of 25 patients receiving monotherapy, and 49 patients receiving the combination. There were 9/24 (37.5%) responses for the single agent, and 25/47 (53%) responses for the combination.²⁵ We included the maximum number of patients from the original trail who had a sufficiently large DNA sample for analysis with DMET.

Characteristics of the 47 patients in this pharmacogenetic study. The parent study enrolled 75 patients in a 2:1 randomization between the two arms. Response rates using the prostate-specific antigen (PSA) Working Group consensus criteria were slightly higher in the subset of patients included in this study when compared with the patients in the parent study.